Considering that the tumor cells are more sensitive than normal tissue cells to high levels of ROS and have a limited capacity to combat oxidative stress [81], it can be speculated that perhaps inhibiting (to some extent) the Nrf2 pathway can bring about a therapeutic gain for cancer cells over normal tissues. This evidence concerns the gene NFE2L2 and neoplasm.